• Explore /
  • Poster
  • / Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

Abstract Poster

Authors

null

David B. Page

Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR

David B. Page , Brie Chun , Joanna Pucilowska , Isaac Kim , Katherine Sanchez , William L Redmond , Zhaoyu Sun , Yaping Wu , Alicia Feryn , Maritza Martel , Christina DiLauro Abaya , Dottie Wadell , Staci L. Mellinger , Nicole Moxon , Walter John Urba , Philomena McAndrew , Maryliza El-Masry , Reva K. Basho , Alison Katherine Conlin , Heather L. McArthur

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02734290

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1015)

DOI

10.1200/JCO.2019.37.15_suppl.1015

Abstract #

1015

Poster Bd #

96

Abstract Disclosures

Similar Posters

First Author: David B. Page

First Author: Yuan Yuan

First Author: Eric P. Winer

First Author: Sara M. Tolaney